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Abstract
Background Among the many consequences of loss of CFTR protein function, a significant reduction of the secretion of 
bicarbonate  (HCO3−) in cystic fibrosis (CF) is a major pathogenic feature. Loss of  HCO3− leads to abnormally low pH and 
impaired mucus clearance in airways and other exocrine organs, which suggests that  NaHCO3 inhalation may be a low-cost, 
easily accessible therapy for CF.
Objective To evaluate the safety, tolerability, and effects of inhaled aerosols of  NaHCO3 solutions (4.2% and 8.4%).
Methods An experimental, prospective, open-label, pilot, clinical study was conducted with 12 CF volunteer participants 
over 18 years of age with bronchiectasis and pulmonary functions classified as mildly to severely depressed. Sputum rheol-
ogy, pH, and microbiology were examined as well as spirometry, exercise performance, quality-of-life assessments, dyspnea, 
blood count, and venous blood gas levels.
Results Sputum pH increased immediately after inhalation of  NaHCO3 at each clinical visit and was inversely correlated with 
rheology when all parameters were evaluated: [G′ (elasticity of the mucus) = − 0.241; G″ (viscosity of the mucus) = − 0.287; 
G* (viscoelasticity of the mucus) = − 0.275]. G* and G′ were slightly correlated with peak flow, forced expiratory volume in 
1 s  (FEV1), and quality of life; G″ was correlated with quality of life; sputum pH was correlated with oxygen consumption 
(VO2) and vitality score in quality of life. No changes were observed in blood count, venous blood gas, respiratory rate, heart 
rate, peripheral oxygen saturation of hemoglobin  (SpO2), body temperature, or incidence of dyspnea. No adverse events 
associated with the study were observed.
Conclusion Nebulized  NaHCO3 inhalation appears to be a safe and well tolerated potential therapeutic agent in the man-
agement of CF. Nebulized  NaHCO3 inhalation temporarily elevates airway liquid pH and reduces sputum viscosity and 
viscoelasticity.
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Key Points 
Inhalation of aerosolized  NaHCO3 was safe and well 
tolerated by CF patients.
There were no significant adverse events associated with 
the intervention.
The apparent benefits of inhaled  NaHCO3 most likely are 
due to its role in raising the pH of the airway surface liq-
uid along with concomitant effects on sputum rheology 
and other parameters.
 C. C. S. Gomez et al.
1 Introduction
In recent years knowledge regarding the pathophysiology of 
pulmonary disease in cystic fibrosis (CF; OMIM: #219700) 
has expanded significantly from studies on ion transport 
by epithelial anion channels in affected tissues [1, 2]. The 
early literature reported that viscous, thick mucus with high 
concentrations of solids that obstructed the airways in CF 
was mainly caused by dehydration of airway surface liq-
uid (ASL) due to dysfunction in chloride transport by the 
CFTR (cystic fibrosis transmembrane conductance regu-
lator) protein and presumably concomitant sodium/water 
hyperabsorption from airway luminal fluid [3], which was 
thought to provide a hypoxic environment favoring bacte-
rial growth [4]. However, recent studies found that defects 
in the CFTR protein also reduced transport of bicarbonate 
 (HCO3−), which is essential for developing and maintain-
ing the physiological properties of mucins [5, 6]. Mucins 
create a gel matrix to lubricate epithelial surfaces and act 
as a barrier against pathogens [7]. Reduction or absence of 
 HCO3− prevents normal expansion and maturation of mucins 
since  HCO3− must be physiologically secreted with mucin 
exocytosis to capture calcium  (Ca2+) and buffer free hydro-
gen  (H+) [8–10]. Reduced  HCO3− may also favor growth of 
bacteria, increased viscous mucus production and biofilm 
formation, and depressed immune responses consequent to 
reduced pH of the ASL [11–13].
In CF, besides the direct effects of low levels of  HCO3− on 
the viscoelastic properties of mucus, other factors such as 
increased elastase, DNA nets, and oxygen free radicals from 
neutrophil apoptosis are released in the airways [7] as a con-
sequence of inflammation and infection, which furthers dete-
rioration of lung function, the primary cause of morbidity 
and mortality in CF [14].
Only relatively recently were the abnormalities of 
mucociliary transport in CF suggested to be caused by a 
 HCO3− deficiency in ASL [8]. In vitro,  NaHCO3 was shown 
to change the rheological properties of sputum [15]. Thus, 
in CF, three factors seem to justify the therapeutic use of 
inhaled  HCO3− aerosol: (1)  HCO3− is critical in the extra-
cellular processing of mucus to attain physiologically rheo-
logical properties [5, 8, 10, 11, 16]; (2) increased ASL pH 
decreases bacterial proliferation [13]; (3) hyperosmotic solu-
tions of  NaHCO3 should help mobilize and remove airway 
surface debris [17, 18].
In this context, the objective of this study was to evaluate 
the safety and tolerability of inhaling aerosolized  NaHCO3 
as the primary outcome in light of its potential effect on clin-
ical and laboratory markers in CF as secondary outcomes.
2  Method
This study was a phase I longitudinal non-randomized, 
unblinded clinical study of inhaled aerosolized  NaHCO3 
with dose escalation in volunteer CF participants per-
formed at a single site. The study determined safety and 
tolerability and assessed clinical and laboratory markers 
following a modified PICOT strategy:
(P) Population: CF patients over 10 years of age with two 
sweat tests with a sweat chloride concentration ≥ 60 meq/L 
and/or two pathogenic variants in the CFTR gene (OMIM: 
#602421). Twelve of 19 volunteers with CF (nine females) 
over 18  years of age were included and followed upto 
completion of the protocol. In addition, nine pancreatic 
insufficient (PI) patients were included. All subjects were 
diagnosed with bronchiectasis from computer-assisted 
tomography (CAT) images of the thorax, with pulmonary 
functions, including forced expiratory volume in 1 s  (FEV1) 
reductions, assessed as mild to severe. Participants included 
in this study were clinically stable, on continuous use of 
oral and/or inhaled antibiotics, and were able to expectorate 
spontaneously (Table 1).
(I) Intervention: Serial doses of 5 mL of 4.2% or 8.4% 
 NaHCO3 dissolved in distilled water were inhaled as an 
aerosol mist.
(C) Control: Temporal analysis in the same individual 
relative to  NaHCO3 administration. There was no placebo, 
active drug, or healthy subjects that served as a control arm.
(O) Outcomes: The primary outcome was safety and toler-
ability of inhaling aerosolized  NaHCO3. In addition, the fol-
lowing parameters were evaluated as secondary outcomes: 
physical/chemical characteristics of sputum, pulmonary 
function, Harvard step-test performance, sputum microbi-
ology, serum electrolytes, blood count, and questionnaire 
scores for assessing quality of life and dyspnea.
(T) Time: Ten weeks. Study parameters were assessed and 
recorded after weekly visits during the 10-week study protocol.
The project (#12398956) was approved by the research 
ethics committee of the Faculdade de Ciências Médicas, 
Universidade Estadual de Campinas. Informed consent 
was obtained from each participant.
2.1  Intervention Model
In the study, each participant underwent a screening visit 
(1) to establish pre-intervention values of parameters to 
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be assessed for effects during and post-intervention, and 
(2) to train for  NaHCO3 inhalation and receive a sup-
ply of 5-mL doses of 4.2% or 8.4%  NaHCO3 solution 
for home inhalation according to the following protocol, 
which was comprised of five treatment regimens in the 
following sequence: (1) 4.2% (once a day) for 2 weeks; 
(2) 4.2% (twice daily) for 2 weeks; (3) 8.4% (once a day) 
for 2 weeks; (4) 8.4% (twice daily) for 2 weeks; (5) no 
 NaHCO3 for 2 weeks (wash-out period). Each patient was 
evaluated clinically during the initial screening visit and 
during each visit after each dose regimen. CF participants 
did not use inhaled hypertonic saline during the interven-
tion, but four patients continued the use of inhaled dornase 
alpha. Inhalation of hypertonic saline was avoided because 
it is used therapeutically to enhance sputum production. 
Even though the mechanisms of action of hypertonic 
saline and  NaHCO3 inhalation are not the same, the con-
comitant use of both drugs would inherently complicate 
the evaluation of the effects of  NaHCO3. No alteration or 
interruption of the participants’ usual treatments occurred 
as a result of the use of  NaHCO3 inhalation during the 
intervention period. However, bicarbonate inhalation was 
scheduled to be the first inhalation treatment of the day, 
and the participants were advised to delay performing res-
piratory physiotherapy immediately after the bicarbonate 
inhalation in order to delay any effects on immediately 
clearing the drug and to avoid the impact of respiratory 
physiotherapy on clearance of airway secretions; both 
factors would complicate the interpretation of effects of 
 NaHCO3 inhalation.
The order of the aerosol solutions was not evaluated. 
Additionally, participants taking inhaled antibiotics at the 
beginning of the study were advised to continue their pre-
scribed use so as to avoid introducing an extraneous variable 
affecting pulmonary function. Participants being treated with 
aerosolized antibiotics were asked to inhale mucolytics first.
Table 1  Clinical and demographic characteristics of participants with cystic fibrosis for inhaled sodium bicarbonate
PI pancreatic insufficiency—assessment of pancreatic status was evaluated measuring fecal elastase in stool or fecal fat in 72-h stool col-
lections in the routine diagnostic tests. Pancreatic enzyme replacement therapy was continued for cystic fibrosis (CF) patients with PI [24]. 
Detailed information regarding the pathogenic variants in the CFTR gene is shown as: G542X-c.1624G>T, p.Gly542X, rs113993959; F508del-
c.1521_1523delCTT, p.Phe508del, rs113993960; A561E-c.1682C>A, p.Ala561Glu, rs121909047; 2183AA>G-c.2051_2052delAAinsG, 
p.Lys684SerfsX38, rs121908799; N1303K-c.3909C>G, p.Asn1303Lys, rs80034486; FEV1 forced expiratory volume in 1 s of the forced vital 
capacity (FVC); CFTR Cystic Fibrosis Transmembrane Conductance Regulator
The spirometry  FEV1 values were classified as mild (> 60%), moderate (41–59%), or severe (≤ 40%)
Patient Age (years) Sex CFTR genotype CFTR class PI FEV1 Discontinued Reason to discontinue
P1 19 Female F508del/G542X II/I No Mild Yes Insufficient sputum
P2 31 Female A561E/A561E II/II Yes Moderate No
P3 29 Female F508del/– II/– No Severe No
P4 18 Male F508del/G542X II/I Yes Moderate Yes Pulmonary exacerbation
P5 17 Male F508del/– II/– No Mild No
P6 24 Male F508del/G542X II/I Yes Moderate No
P7 26 Male 2183AA>G/N1303 K I/II Yes Severe Yes Did not complete study stages
P8 20 Female F508del/F508del II/II Yes Severe No
P9 16 Female F508del/– II/– Yes Severe Yes Use of oxygen
P10 19 Female F508del/– II/– No Mild No
P11 13 Male F508del/– II/– Yes Mild Yes The participant did not have 
time to participate in the 
study
P12 19 Male F508del/F508del II/II Yes Severe No
P13 21 Male F508del/– II/– Yes Mild No
P14 23 Female F508del/G542X II/I Yes Moderate Yes Pulmonary exacerbation
P15 28 Male F508del/– II/– Yes Severe No
P16 43 Male F508del/F508del II/II Yes Severe Yes The participant did not have 
time to participate in the 
study
P17 21 Male F508del/F508del II/II Yes Mild No
P18 26 Female F508del/F508del II/II Yes Severe No
P19 22 Male F508del/F508del II/II Yes Moderate No
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2.2  Clinical and Laboratory Markers
2.2.1  Elasticity, Viscosity, and pH of Sputum
Sputum was collected during all visits at intervals of 
30 min over a 180-min period after the inhalation treat-
ment as well as before and after the spirometry tests and 
Harvard step tests. A minimum sputum specimen of 3 mL 
was collected in a 15-mL sterile tube and frozen in dry 
ice for storage and transport. Rheological analysis evalu-
ated specimen: (1) elasticity − G′ (stiffness); (2) viscosity 
− G″ (flow resistance); and (3) viscoelastic modulus − G* 
[15, 19] (see Electronic Supplementary Material (ESM) 
1). The rheology analysis was performed using a Haake 
RheoStress 1 rheometer (Thermo  Scientific®, Waltham, 
MA, USA), according to the manufacturer’s instructions. 
All rheology analyses were performed at the Department 
of Physics and Chemistry, Instituto de Química, Univer-
sidade Estadual de Campinas.
The pH was measured concomitantly with the rheology 
in a ST2100 pH meter  (OHAUS®, Parsippany, NJ, USA) 
using a pH electrode  (Digimed®, São Paulo, Brazil) made 
specifically for fluids containing protein, fat, and/or creams. 
Room temperature was maintained at 23 °C. Specimens 
were equilibrated with room air and temperature, but not 
controlled for  CO2 tension.
2.2.2  Microbiology of Sputum
A semi-quantitative analysis was made of bacteria in the 
sputum specimens collected at the initial screening visit, 
V0, and at the final visit, V5. The bacterial load was classi-
fied as (1) +: light; (2) ++: moderate; and (3) +++: heavy. 
All specimens were assayed for the presence of mucoid and 
non-mucoid Pseudomonas aeruginosa and Staphylococcus 
aureus.
2.2.3  Spirometry
Spirometry was performed according to the American Tho-
racic Society and European Respiratory Society guidelines 
using a  Koko® Spirometer (nSpire Health, Longmont, CO, 
USA) [20]. At least three well-defined and reproducible 
maximum flow-volume loops were obtained: (1) before, 
(2) after administering the bronchodilator Salbutamol 
 (C13H21NO3, 400 µg), and (3) after conducting the Harvard 
step-test exercise. The following parameters were measured: 
forced expiratory volume in 1 s  (FEV1), forced vital capacity 
(FVC), and forced expiratory flow rate between 25 and 75% 
of the FVC  (FEF25–75%). The best result of three sequential 
exhalation efforts was recorded.
2.2.4  Peak Flow
Participants used a peak-flow meter according to the 
guidelines of the American Lung Association [21]. The 
best of three measurements taken during the clinic visits 
and at home (twice daily) were recorded.
2.2.5  Harvard Step Test
The step height was set at 30 cm (kikos™, São Paulo, 
Brazil). The following parameters were recorded:
1. Fitness index (FI) calculated as [(100 × test duration in 
s)/(2 × sum of heart beats in the recovery period)], which 
was classified as: excellent (> 90), good (80–89), above 
average (65–79), low (55–64), or insufficient (< 55).
2. Maximum oxygen consumption calculated as (VO2 
max (mL/kg/min) calculated as 0.2 × (stepping 
rate) + [1.33 × 1.8 × (step height in meters) × (steps fre-
quency/min)] + 3.5 (resting component).
3. Energy expenditure calculated as  [VO2max (mL/kg/
min) × weight (kg)]/1000 × 5 kcal/L], which converts 
VO2 max into expended energy (kcal/min).
2.2.6  Cystic Fibrosis (CF) Quality‑of‑Life Questionnaire 
(CFQoLQ) and San Diego Questionnaire (SDQ) 
for Dyspnea
Participants answered the standard questionnaire at all 
visits [22, 23].
2.2.7  Adverse Events
To assess the tolerability and possible side effects of inhal-
ing aerosolized  NaHCO3 over time, participants completed a 
daily recall form (medications administered; visual analogue 
scale for dyspnea; cough activity; respiratory congestion, as 
well as other clinical indicators including pulmonary exac-
erbations, sinusitis, hemoptysis, malaise or lack of energy, 
weight loss, fever, absence from work/school.
At all visits, the following were measured: heart rate, 
respiratory rate, peripheral oxygen saturation of hemo-
globin  (SpO2), weight, arterial blood pressure, and body 
temperature. In addition, an automatic blood cell count 
(red blood cell, white blood cells, and platelets) as well as 
venous blood gas levels were obtained at the initial visit, 
V0, and the final visit, V5.
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2.2.8  Statistical Analysis
Statistical analysis was performed using the Statisti-
cal Package for the Social Sciences version 24.0 (IBM 
Corp. Released 2016. IBM SPSS Statistics for Windows, 
Armonk, NY, USA). The statistical design is shown in 
ESM 1.
3  Results
Initially, 19 volunteer participants with CF, who were not 
using aerosolized hypertonic saline inhalation therapy, were 
enrolled. Seven of these 19 volunteers were excluded from 
the study due to complicating conditions: (1) insufficient 
sputum production to perform the rheology measures (n = 1), 
(2) poor adherence to the protocol (n = 1) (participant used 
less than 80% of the drug dose); (3) oxygen therapy required 
prior to beginning the intervention (n = 1) [oxygen therapy 
was prescribed by a physician at the screening visit, V0, 
and the trial investigator was informed], (4) insufficient time 
for weekly visits (n = 2), (5) pulmonary exacerbations at the 
onset of the study (n = 2) [during the clinical evaluation two 
physicians concluded the incidents observed as exacerba-
tions were ongoing with prior bacterial colonization. Even 
though it seems unlikely, we cannot discard the possibility 
that the intervention was a contributing factor, and we note 
them as possible adverse events. Importantly, the exacerba-
tion appeared during the first period of inhalation and was 
noted as a clinical finding during the first visit, V1. Con-
sequently, both patients were excluded from the study and 
no data were collected from these patients]. All 12 partici-
pants who completed the protocol were more than 18 years 
of age and were diagnosed with bronchiectasis; five were 
female; nine were pancreatic insufficient. Their spirometry 
 FEV1 values were classified as mild (> 60%; n = 6), mod-
erate (41–59%; n = 5), or severe (≤ 40%; n = 8) (Table 1). 
Four patients continued inhaling aerosolized dornase alpha 
as therapy during the protocol.
To assess adherence, the participants responded to a ques-
tionnaire concerning their routine healthcare. An additional 
questionnaire with subjective questions regarding fatigue, 
daily sputum characteristics, and symptoms associated with 
dyspnea were scored. Incomplete questionnaires delivered 
during the visits were interpreted as insufficient interest to 
participate in the study. Concomitantly, the drug supplied to 
the participant was dated with the correct day for use, and 
the participant was instructed to return all empty and full 
vials to the study personnel on each subsequent visit.
Pertaining directly to the safety and tolerability of inhal-
ing aerosolized  NaHCO3, no changes were observed in: com-
plete blood count, venous blood gas, heart rate, respiratory 
rate,  SpO2, body temperature, or the dyspnea questionnaire 
(data not shown; p ≥ 0.05). Participants reported no serious 
adverse events. One participant complained of a burning 
sensation on the lips, which was resolved by ingesting water 
during inhalation, and recommending exhaling outside the 
mouthpiece. Two participants reported cough during the first 
inhalation, which did not re-occur subsequently.
3.1  Rheology, Spirometry, Microbiology
Comparison of the rheology values (G′, G″, and G*) 
between visits and during the visits did not show significant 
differences (p > 0.05) (ESM 2). Spirometry and microbiol-
ogy results did not differ during the intervention (Table 4; 
ESM 3).
3.2  pH
After  NaHCO3 was inhaled, the pH of the first specimen 
of sputum taken each day was the highest of all subsequent 
specimens and showed statistically higher values in visits 
V3 and V4 than at the screening visit (V0) (8.4%, p = 0.004 
and 0.001) (Table 2; Fig. 1). Furthermore, at all visits after 
inhalation of  NaHCO3 aerosol, the mean pH of samples col-
lected between time zero and 180 min decreased with time 
to the pH of the screening sample at V0 (p < 0.05) (Table 2). 
Despite being an exploratory and underpowered analysis, 
an inverse correlation was observed between pH and rheol-
ogy markers when all data were considered (G′ = − 0.241; 
G″ = − 0.287; G* = − 0.275) (Table  5) and the mean 
value obtained at each visit (G′ = − 0.312; G″ = − 0.384; 
G* = − 0.336) (p < 0.001) (ESM 4). Oxygen consumption 
(p = 0.025), energy expenditure (p = 0.024), quality-of-life 
markers [treatment burden (p = 0.010); health perceptions 
(p = 0.011) and total score (p = 0.009)] showed improvement 
during the intervention period (Tables 2, 3). Other signifi-
cant correlations were obtained with markers for: (1) G* 
versus peak flow,  FEV1, quality of life (vitality, social, eat-
ing disturbances, and respiratory scores); (2) G′ versus peak 
flow, FVC,  FEV1 (before and after the Harvard step test), 
quality of life (vitality, social, eating disturbances, and res-
piratory scores); (3) G″ versus quality of life (vitality, social, 
eating disturbances, and respiratory scores); (4) pH versus 
 VO2, vitality score in quality of life (ESM 4). Small corre-
lations could be evidence of alterations in rheology (beside 
being a minimum change) with inhaled use of  NaHCO3 that 
minimally alters the sputum pH for a brief period.
Spearman correlations between the values for dyspnea, 
peak flow, Harvard step test, spirometry, and quality of life 
and between the values for spirometry and quality of life 
of participants with CF during the protocol with inhaled 
bicarbonate can be seen, respectively, in ESM 5 and ESM 
6. All positive correlations were small, and more studies 
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need to be carried out to confirm these exploratory find-
ings (Tables 4, 5).
No changes were observed in blood count, venous blood 
gas, respiratory rate, heart rate,  SpO2, body temperature, 
or incidence of dyspnea.
Importantly, no adverse events associated with the 
study were observed.
4  Discussion
This in vivo clinical study assesses the safety, tolerability, 
and effects of  NaHCO3 inhalation in subjects with CF. 
The pH and rheological properties of sputum as well as 
clinical/laboratory data were evaluated before, during, and 
Table 2  Values for expectorated sputum pH, peak flow, and Harvard step test of participants with cystic fibrosis before (screening) and after 
inhaled bicarbonate protocols
Visits: All visits occurred immediately after completing the indicated inhalation regimen. Each regime was conducted for a period of 2 weeks. 
Visit 1: aerosolized 4.2%  NaHCO3 inhaled once a day. Visit 2: 4.2% twice daily. Visit 3: 8.4%  NaHCO3, inhaled once a day. Visit 4: 8.4% 
 NaHCO3, inhaled twice daily, Visit 5: after 15 days of washout with no inhaled  HCO3−
*Statistical analysis was performed by ANOVA with repeated measures by multivariate tests (Pillai’s trace, Wilks’ lambda, Hotelling’s trace, 
and Roy’s largest root), with post hoc pairwise analysis by the Bonferroni test. The covariance matrix of the transformed and orthonormalized 
dependent variable error was evaluated by Mauchly’s sphericity test
**Statistical analysis performed by Friedman’s two-way analysis of variance by paired sample stations. All participants were included in the 
evaluation. Significant p value is in bold. Alpha = 0.05
a Data given as mean ± SD
b Combined analysis—first line shows the arithmetic mean for the data collected during visits at 30-min intervals for 180 min. Second line shows 
mean for visits 1–4
c In the post-inhalation period, sputum pH collected during screening was significantly lower compared to visit 3 (p = 0.026) and visit 4 
(p = 0.02). At visit 5, the pH value was significantly lower than the value observed at visits 2, 3, and 4 (p = 0.011, 0.050, 0.015, respectively)
d At visit 3, the first collection had a higher pH value compared to all others—30  min (p = 0.001), 60  min (p = 0.002), 90  min (p = 0.008), 
120 min (p = 0.034), 150 min (p = 0.015), 180 min (p = 0.021)
e At visit 4, the first collection had a higher pH value when compared to later collections—30  min (p = 0.003), 60  min (p = 0.004), 90  min 
(p = 0.001), 120 min (p = 0.004), 150 min (p = 0.001), 180 min (p = 0.003)
f No difference was observed between the all-pairwise test groups by the Bonferroni method
g VO2 was lower in the intervention period when compared to the post-intervention period (p = 0.030)
h Work was higher after the intervention period when compared to the period during the intervention (p = 0.030)
pH of sputum Screeninga Visit 1 (4.2% 
once a day)a
Visit 2 (4.2% 
twice daily)a
Visit 3 (8.4% 
once a day)a
Visit 4 (8.4% 
twice daily)a
Visit 5 (wash-
out)a
p value
Time collected
Baseline 7.333 ± 0.361 7.560 ± 0.492 7.888 ± 0.347 7.851 ± 0.341 7.999 ± 0.293 7.219 ± 0.382 0.039*c
30 min 7.417 ± 0.313 7.559 ± 0.289 7.469 ± 0.417 7.557 ± 0.284 0.375*
60 min 7.438 ± 0.270 7.426 ± 0.386 7.328 ± 0.241 7.317 ± 0.409 0.646*
90 min 7.338 ± 0.332 7.413 ± 0.399 7.370 ± 0.306 7.213 ± 0.351 0.878*
120 min 7.503 ± 0.390 7.248 ± 0.431 7.425 ± 0.375 7.235 ± 0.388 0.125*
150 min 7.341 ± 0.383 7.229 ± 0.499 7.401 ± 0.325 7.245 ± 0,0.395 0.466*
180 min 7.333 ± 0.257 7.257 ± 0.368 7.338 ± 0.308 7.257 ± 0.400 0.953*
p value 0.225* 0.090* 0.004*,d 0.011*,e
Peak flow 398.75 ± 124.06 413.00 ± 114.97 427.08 ± 149.40 436.25 ± 136.70 405.42 ± 134.90 423.75 ± 147.14 0.037*f
Harvard step test
Fitness 47.78 ± 6.24 48.68 ± 7.35 49.92 ± 8.38 45.22 ± 12.06 49.04 ± 7.01 49.35 ± 5.40 0.504*
 VO2 (oxygen 
consumption)b
121.24 ± 22.25 122.18 ± 22.94 122.18 ± 33.04 121.64 ± 41.94 127.38 ± 25.90 131.21 ± 27.32 0.112*
 Work (energy 
expenditure)b
31.62 ± 8.73 32.30 ± 8.98 32.24 ± 10.69 32.46 ± 13.43 33.64 ± 9.77 34.78 ± 10.60 0.052*
Fitness 47.78 ± 6.24 48.22 ± 7.82 49.35 ± 5.40 0.417*
 VO2 (oxygen 
consumption)b
121.24 ± 22.25 123.35 ± 27.93 131.21 ± 27.32 0.025*g
 Work (energy 
expenditure)b
31.62 ± 8.73 32.66 ± 10.20 34.78 ± 10.60 0.024*h
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after interventions with inhaled aerosols of two concentra-
tions (4.2% and 8.4%) of solutions of  NaHCO3 with a dose 
escalation every 2 weeks for eight consecutive weeks.
The data show that inhaled  NaHCO3 acutely raised the 
pH of sputum, which correlated well with all rheological 
moduli (G′, G″, and G*). In addition, other markers, includ-
ing quality of life and the Harvard step test, improved sig-
nificantly during the study intervention period.
NaHCO3 is essential for proper expansion and maturation 
of mucin granules [8, 11, 16]. In addition, mucin granules 
are influenced by many factors, such as hydration, pH, solu-
tion ionic strength, composition, concentration, electrostatic 
interactions between mucins, size of polymers, degree of 
cross-linking, debris, etc. [25].
In a study on the effect of mixing  NaHCO3 solution 
directly with the sputum of CF patients in vitro, Stigliani 
et al. [15] reported reductions in rheological moduli G′, G″, 
and G*. However, the present study evaluated native expec-
torated sputum. In the samples from the same participant 
and among the participants, quantitative/qualitative mac-
roscopic variability was observed, particularly in the vol-
ume of expectorations. The large variability in properties 
between individual sputum specimens will likely require a 
much larger population to firmly establish statistically sig-
nificant changes resulting from inhaled  NaHCO3 aerosols. 
Nonetheless, in the present small population, the results 
between screening V0 and after washout V5 often indicated 
a statistically significant change in sputum properties such 
as pH at visits V2–V4 that may be clinically important for 
future studies.
The variability of sputum rheology is multifactorial, 
including physicochemical aspects, and may be affected 
by: (1) repetitive voluntary cough, which may change the 
solid content and alter mucus hydration in the airways; (2) 
surface tension; (3) surface contact time with the respira-
tory airways; (4) adherence to bronchial wall [26]. The most 
direct method to obtain sputum may be bronchoscopy with 
bronchoalveolar lavage; however, due to ethical considera-
tions and the probable change in properties of the mucus as a 
consequence of the saline wash to remove the native sputum, 
this method was not used [19]. The bicarbonate solution is 
hyperosmotic and may draw fluid into the airway surface 
liquids (ASL) as is thought to occur with hypertonic saline, 
thereby “thinning” the ASL and its contents. Again, like 
hypertonic saline, it may act as a minor irritant and stimulate 
airways secretions too.
Although native expectorated sputum was evaluated, the 
gel component of sputum in rheological analysis is critically 
important. Recent studies [27, 28] describe a positive corre-
lation of the gel component with the G′, G″, and G* moduli. 
Here, liquids and saliva largely separated spontaneously 
from the gel component of the sputum when compressed 
between the rheometer plates supporting the presumption 
that measurements principally reflect gel (mucus) properties. 
Rheological differences in sputum from patients with CF, 
chronic obstructive pulmonary disease, and acute pulmonary 
infections have been reported [19]. During pulmonary exac-
erbations, elasticity and viscosity are increased, and return 
to basal levels only after antibiotic therapy along with nor-
malization of pulmonary function [29].
An important finding herein is that an increase in sputum 
pH immediately accompanies  NaHCO3 inhalation. Lower 
pH of ASL favors bacterial growth. A recent study in a por-
cine CF model found the growth of micro-organisms in CF 
was enhanced significantly in reduced extracellular fluid pH 
resulting from decreased secretion of  HCO3− [13]. Presently, 
we are not able to establish that higher pH associated with 
the interventions here inhibited bacterial growth; further 
studies are needed for confirmation.
A
B
V0
Screening
pH
pH 
V1 V2 V3 V4 V5
Washout
V0 
Screening
V1 V2 V3 V4 V5
Washout
Fig. 1  a pH of induced sputum of participants with cystic fibrosis 
during the period of intervention with inhaled bicarbonate aerosol. 
The data show as a marker in the figure the increase of 0.5 pH units 
during the intervention with 8.4%  NaHCO3. The complete data are 
shown in Table 2. b Change in each individual’s sputum pH at base-
line measurement with trend lines. Screening visit; (V1) 4.2% (once a 
day) over 2 weeks; (V2) 4.2% (twice daily) over 2 weeks; (V3) 8.4% 
(twice daily) over 2  weeks; (V4) 8.4% (twice daily) over 2  weeks; 
(V5) no drug—wash-out period. In the post-inhalation period, spu-
tum pH collected during screening was significantly lower compared 
to visit 3 (p = 0.026) and visit 4 (p = 0.02). At visit 5 (washout), the 
pH value was significantly lower than the values observed at visits 
2, 3, and 4 (p = 0.011, 0.050, 0.015, respectively). Statistical analysis 
was performed by ANOVA with repeated measures by multivariate 
tests (Pillai’s trace, Wilks’ lambda, Hotelling’s trace, and Roy’s larg-
est root), with post hoc pairwise analysis by the Bonferroni test. The 
covariance matrix of the transformed and orthonormalized dependent 
variable error was evaluated by Mauchly’s sphericity test. All partici-
pants were included in the evaluation. Alpha = 0.05
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Table 3  Quality-of-life scores from subjects with cystic fibrosis during the protocol with inhaled bicarbonate
*Statistical analysis performed by Friedman’s two-way analysis of variance by paired sample stations. In the comparison with the pairwise 
method between groups with significant p values (p values adjusted for multiple comparisons): treatment—the score was lower before inter-
vention when compared to the post-intervention period (p = 0.018); health—in the simultaneous analysis for all groups, no significant asso-
ciation was observed; however, in grouped data, a lower score was obtained before the intervention compared to the post-intervention period 
(p = 0.043); digestive—no significant association in the analysis; Overall total in the simultaneous analysis for all groups the score was signifi-
cantly lower before the intervention compared to the post-intervention period (p = 0.034). The analysis for the grouped data similarly was signifi-
cantly different (p = 0.007). Significant p values are in bold. Alpha = 0.05
a Combined analysis gives the arithmetic mean for the data collected from all subjects during each separate visit, then the arithmetic mean of all 
visits after regimens one to four were calculated together
b Visits: Each visit occurred after 2  weeks on each regime indicated. Visit 1: 4.2%  NaHCO3 aerosol was inhaled once a day. Visit 2: 4.2% 
 NaHCO3, aerosol was inhaled twice daily; Visit 3: 8.4%  NaHCO3, aerosol was inhaled once a day; Visit 4: 8.4%  NaHCO3 aerosol was inhaled 
twice daily. After last day of 8.4% inhalations, no  NaHCO3 was inhaled during the 15 days before the evaluation at Visit 5. Data presented as 
medians (25th percentile–75th percentile)
Markera Screening Visit 1 (4.2% 
once a day)b
Visit 2 (4.2% 
twice daily)b
Visit 3 (8.4% 
once a day)b
Visit 4 (8.4% 
twice daily)b
Visit 5 (wash-
out)b
p value*
Physical func-
tioning
52.05 (38.53–
84.30)
58.30 (40.55–
82.28)
58.15 (50.00–
81.25)
60.25 (42.65–
70.80)
60.40 (46.85 to 
89.55)
56.20 (43.70 to 
85.35)
0.499
Physical role 83.30 (75.00–
97.90)
91.60 (70.78–
97.80)
91.60 (91.60–100) 83.30 (66.60–100) 91.60 (77.08 to 
100)
84.45 (83.30 to 
97.90)
0.146
Vitality 58.30 (50.00–
72.90)
66.60 (51.38–
75.00)
66.60 (52.08–
75.00)
66.60 (52.08–
75.00)
75.00 (50.00 to 
83.30)
70.80 (52.80 to 
83.30)
0.452
Emotional func-
tioning
73.30 (60.00–
85.78)
80.00 (60.00–
84.95)
76.65 (61.65–
82.48)
80.00 (61.65–
86.60)
76.65 (61.65 to 
91.63)
73.30 (60.00 to 
85.78)
0.630
Social 58.30 (50.00–
77.70)
66.60 (50.00–
81.90)
69.40 (52.88–
87.43)
74.95 (51.38–
88.80)
66.60 (51.38 to 
86.03)
69.40 (45.80 to 
81.90)
0.461
Body image 61.05 (33.30–
97.20)
66.60 (44.40–100) 66.60 (47.18–100) 66.60 (27.75–100) 72.15 (36.08 to 
100)
72.15 (30.53 to 
100)
0.775
Eating distur-
bances
100 (77.70–100) 94.40 (77.70–100) 100 (83.28–100) 100 (100–100) 100 (100 to 100) 100 (77.70 to 100) 0.312
Treatment burden 44.40 (36.08–
66.60)
55.50 (36.08–
77.70)
55.50 (36.08–
77.03)
55.50 (36.08–
66.60)
55.50 (33.30 to 
66.60)
55.50 (55.50 to 
66.60)
0.131
Health percep-
tions
44.40 (33.30–
55.50)
44.40 (33.30–
66.60)
61.05 (36.08–
74.93)
61.05 (36.08–
82.95)
61.05 (27.75 to 
66.60)
49.95 (36.08 to 
82.03)
0.011
Weight 16.65 (0–100) 66.60 (8.33–100) 66.60 (33.30–100) 83.30 (8.33–100) 49.95 (0 to 100) 66.60 (8.33 to 
100)
0.246
Respiratory 
symptoms
66.60 (56.90–
66.60)
63.85 (55.53–
72.20)
66.60 (61.10–
74.30)
72.20 (58.28–
72.20)
63.85 (55.50 to 
72.20)
69.40 (61.10 to 
77.70)
0.829
Digestive symp-
toms
88.80 (77.70–100) 100 (80.48–100) 100 (77.70–100) 100 (72.15–100) 100 (80.48 to 100) 77.70 (66.60 to 
100)
0.203
Total 64.86 (56.04–
73.76)
67.78 (63.90–
78.20)
73.14 (67.66–
73.14)
70.77 (62.35–
82.30)
72.20 (65.14 to 
79.12)
72.20 (58.04 to 
82.12)
0.027
Markera Screening Visits 1–4 Visit 5 p value*
Physical functioning 52.05 (38.53–84.30) 57.19 (46.86–79.92) 56.20 (43.70–85.35) 0.266
Physical role 83.30 (75.00–97.90) 89.55 (80.17–96.85) 84.45 (83.30–97.90) 0.284
Vitality 58.30 (50.00–72.90) 67.66 (52.94–76.53) 70.80 (52.80–83.30) 0.266
Emotional functioning 73.30 (60.00–85.78) 78.31 (60.40–83.91) 73.30 (60.00–85.78) 0.931
Social 58.30 (50.00–77.70) 67.28 (53.18–86.38) 69.40 (45.80–81.90) 0.377
Body image 61.05 (33.30–97.20) 70.76 (38.16–99.30) 72.15 (30.53–100) 0.670
Eating disturbances 100 (77.70–100) 98.60 (92.33–100) 100 (77.70–100) 0.834
Treatment burden 44.40 (36.08–66.60) 56.89 (42.32–69.21) 55.50 (55.50–66.60) 0.010
Health perceptions 44.40 (33.30–55.50) 56.89 (33.30–69.38) 49.95 (36.08–82.03) 0.030
Weight 16.65 (0–100) 54.13 (20.81–100) 66.60 (8.33–100) 0.228
Respiratory symptoms 66.60 (56.90–66.60) 65.24 (60.57–71.50) 69.40 (61.10–77.70) 0.502
Digestive symptoms 88.80 (77.70–100) 94.43 (83.28–100) 77.70 (66.60–100) 0.015
Total 64.86 (56.04–73.76) 71.97 (66.60–78.39) 72.20 (58.04–82.12) 0.009
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In healthy subjects, the pH of ASL was reported to range 
from 6.85 to 7.65 [30, 31], but in CF, the range was reported 
to be 4.5–8.5 [31]. In the present study,  NaHCO3 inhalation 
raised the sputum pH significantly in all visits and to ~ 7.9 
in the last three visits, which is higher than the maximum 
value reported for healthy subjects (7.65). The duration of 
the raised pH effect of the inhalation (which required about 
15–20 min to inhale nebulized the dose) was approximately 
150 min. Therefore, increasing the frequency of  NaHCO3 
inhalations should be tested (every 4–6 h dosing); consider-
ing that most patients are prescribed airway clearance ther-
apy two to three times per day, more frequent bicarbonate 
dosing may be feasible, but a search for alternative formu-
lations that might allow a longer duration of action seems 
justifiable. A corroborating increase in pH due to  NaHCO3 
in vitro has been described [15].
The most favorable pH for growth and maintenance of 
bacterial colonization/infection in CF lungs is uncertain. 
However, it is commonly accepted that in CF a low volume 
of ASL and/or its acidity due to lack of  HCO3− changes 
mucociliary clearance and favors pulmonary infection [1, 
32–34]. Recent findings of acidity on the airway luminal 
epithelium in CF affirms the development of poor muco-
ciliary clearance and infection [8, 13, 35, 36]. In contrast, 
others have reported that airway pH in CF is not different 
from that of healthy subjects [37, 38]. In short, bacteria 
decreased in 11 assays, increased in seven assays, and 
remained unchanged in 17 assays.
Using  FEV1 as a principal clinical marker, higher vis-
coelasticity of mucus appears to contribute to pulmonary 
obstruction and reduced lung function [39]. This marker 
was followed in multicenter studies of inhaled hypertonic 
saline and dornase alpha to demonstrate  FEV1 increased 
with these drugs [40]. Although the present study did 
not reach statistical significance, two participants had 
improved  FEV1 after inhaling  NaHCO3 (data not shown); 
thus, for a more compelling analysis of  FEV1 responses, 
a larger sample size and follow-up study, possibly for a 
longer duration of treatment, are required.
Quality of life is a marker widely used in intervention 
studies for new drugs as it provides personalized patient 
input [41, 42]. As a consequence of the results considered 
above, a cascade of events may occur that affect the quality 
of life. Lower pH changes the immune response in airways, 
and increases bacterial colonization favoring biofilm for-
mation with a consequent increase in inflammation/infec-
tion, airway obstruction, and worsening of quality of life 
Table 4  Microbiological characterization of sputum from participants with cystic fibrosis before and after the intervention period with inhaled 
sodium bicarbonate
A semi-quantitative analysis of bacterial content in the sputum specimens was performed at the initial screening visit (pre) and at the final visit 
5 (post). The bacterial load was classified as: + light; ++ moderate; +++ heavy. The S. aureus load was reduced in five participants; mucoid P. 
aeruginosa was reduced in four participants, and non-mucoid P. aeruginosa was reduced in two participants. However, five participants and 
two participants showed an increased bacterial load with non-mucoid P. aeruginosa and mucoid P. aeruginosa, respectively. Overall, bacteria 
decreased in 11 assays, increased in seven and remained unchanged in 17 assays
Patient Non-mucoid
Pseudomonas aeruginosa
Mucoid
P. aeruginosa
Staphylococcus aureus
Pre Post Pre Post Pre Post
P2 ++ + ++ ++
P3 ++ ++
P5 ++ + ++ + +++ ++
P6 +++ ++
P8 ++ +++ ++ +++
P10 + ++ + ++ ++ ++
P12 +++ +++ +++
P13 +++ ++
P15 + ++ + +
P17 + + + +++ +
P18 ++ + +++ +
P19 +++ ++
Table 5  Spearman correlation between pH and rheology values for 
all sputum specimens analyzed (n = 360) between and during all vis-
its of patients with cystic fibrosis during the inhalation regimens with 
inhaled bicarbonate
Significant p value in bold. Alpha = 0.05
G* G′ G″ G′- G″
pH Correlation 
coefficient
− 0.241 − 0.287 − 0.275 − 0.214
p value < 0.001 < 0.001 < 0.001 < 0.001
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[43–45]. Of note, the highest rheology values (increased 
viscoelasticity) were associated with worsening dyspnea, 
but correlations were weak.
Low tolerability to physical exercise is a common effect 
of CF, which increases with disease severity and is related 
to a higher mortality rate [46]. The Harvard step test is an 
accepted tool to evaluate tolerability to physical exercise 
[47]. Higher values of this measure related to a lower inci-
dence of cardiopulmonary disease and better predisposition 
or physical activity [48, 49]. Here, the Harvard step test 
showed an improvement in oxygen consumption and energy 
expenditure after the intervention with inhaled  NaHCO3 
(Table 2). In spite of being an exploratory analysis, our data 
indicated an improvement in both oxygen consumption and 
energy expenditure that appeared to be related to the inter-
vention and could be associated with a better capacity to 
perform daily life activities with inhaled  NaHCO3.
In brief, as reported in Sect.  2, an exacerbation was 
observed during the first period of inhalation in two patients 
and was noted as a clinical finding during the first visit, V1. 
An incidence of exacerbations in patients with CF might be 
expected to be greater than two of 19 potential subjects in 
this timeframe. Thus, it seems reasonable that these events 
preceded the intervention and were not caused by it. Conse-
quently, both patients were excluded from the analysis and 
no data were collected from these patients. It is important 
to note that no further incidence of exacerbations occurred 
at any time in any of the remaining participants during the 
10 weeks of the study.
4.1  Study Limitations
The apparent limitations of this study include: (1) inadequate 
sample size to confirm or reject correlations and establish 
intervention effects. However, a recent study of 12 patients 
with CF showed that acute and longitudinal changes in lung 
function correlated with mucus rheology in spite of very 
heterogenous parameters among the patients [29]. (2) Sub-
optimal sputum separation (saliva, mucus gel, air) to perform 
precision rheological assays. (3) Lack of a placebo and/or 
active control group (e.g., hypertonic saline). (4) Short-term 
follow-up for a more robust identification of clinical markers 
such as lung function. (5) Older patients with more severe 
lung disease that may obscure lung function improvements, 
in view of likely irreversible damage to airways and lung 
parenchyma. (6) Alkalization of ASL may impede bacteria 
growth; therefore, we collected specimens for culture only 
after V5, the fifth and final visit (wash-out). It seems possible 
that sputum cultures at the end of V4 would have been more 
appropriate for evaluating acute versus longer term microbio-
logical effects. (7) During the trial interventions we did not 
collect blood for complete blood counts or venous blood gas.
The study limitations might be reduced by: (1) increas-
ing the sample size and follow-up time with the inclusion 
of more than one center. (2) Selecting participants without 
extremely severe disease; including younger participants 
with less severe airway pathology. (3) Further exploration 
for optimal intervention duration, dose concentration, and 
inhalation frequency for  NaHCO3 (dose-escalation study). 
(4) Evaluating mucins and inflammatory markers in fresh, 
native sputum at the time of collection.
5  Conclusion
This study documents that inhalation of aerosolized 
 NaHCO3 is safe and very well tolerated by CF participants. 
There were no significant adverse events associated with the 
interventions, even at the highest dosage of 5 mL saturated 
solution of  NaHCO3 (8.4%) inhaled twice daily. However, 
due to the small number of participants and inherently wide 
range in values of measured parameters, for example, spu-
tum specimen (rheology/pH), spirometry, fitness, microbi-
ology, and other variables in the population, the effects of 
the intervention merit further studies in a larger number of 
subjects to reveal and establish the potential therapeutic ben-
efits that are suggested here. The apparent benefits of inhaled 
 NaHCO3 are due most likely to its effects on raising the pH 
of the ASL and on improving sputum rheology as a function 
of more fully expanded mucin and DNA macromolecules 
in the presence of higher concentrations of  HCO3− in the 
ASL. These changes would enhance the respiratory immune 
defense and favor improved mucociliary clearance of the 
airways in maintaining improved airway hygiene.
In conclusion, even though most measured parameters 
did not achieve statistical significance, the means of the 
measurements of effects almost always remained constant 
or changed in the direction of presumed improvement, giv-
ing confidence that the treatment did not depress or impede 
normal function. The favorable changes observed in several 
parameters in this study may support inhalation of nebulized 
 NaHCO3 as a safe and well-tolerated therapeutic agent in 
the management of CF and possibly other obstructive lung 
diseases.
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